Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | DRD1 | P21728 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16488711 | 1.00 | NFKB1 (0.40) | NFKB1NFKB2RELACETPDRD2 | |
| SCHEMBL16488708 | 0.88 | NFKB1 (0.39) | NFKB1NFKB2RELACETP | |
| SCHEMBL15326614 | 0.88 | NFKB1 (0.39) | NFKB1NFKB2RELACETP | |
| SCHEMBL18649496 | 0.87 | NFKB1 (0.46) | NFKB1NFKB2RELACETPDRD2 | |
| SCHEMBL21179904 | 0.84 | NFKB1 (0.36) | NFKB1NFKB2RELA | |
| SCHEMBL16489532 | 0.84 | NFKB1 (0.34) | NFKB1NFKB2RELA | |
| Myricanone SCHEMBL29904784 | 0.81 | NFKB1 (0.60) | NFKB1NFKB2RELACETP | |
| Myricanone SCHEMBL432252 | 0.81 | NFKB1 (0.60) | NFKB1NFKB2RELACETP | |
| SCHEMBL21692990 | 0.81 | NFKB1 (0.40) | NFKB1NFKB2RELACETPDRD2 | |
| SCHEMBL21179905 | 0.80 | NFKB1 (0.33) | NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358405-B2 | Myricanol derivatives and uses thereof for treatment of neurodegenerative diseases | UNIVERSITY OF SOUTH FLORIDA (US) | 2019-07-23 | — | — | US | disclosed |
| US-20190218165-A1 | Myricanol Derivatives and Uses Thereof for Treatment of Neurodegenerative Diseases | UNIV SOUTH FLORIDA (US) | 2019-07-18 | — | — | US | disclosed |
| US-10287227-B2 | Myricanol derivatives and uses thereof for treatment of neurodegenerative diseases | UNIVERSITY OF SOUTH FLORIDA (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180037529-A1 | Myricanol Derivatives and Uses Thereof for Treatment of Neurodegenerative Diseases | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2018-02-08 | — | — | US | disclosed |
| US-20180037529-A1 | Myricanol Derivatives and Uses Thereof for Treatment of Neurodegenerative Diseases | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2018-02-08 | — | — | US | disclosed |
| US-9598338-B2 | Myricanol derivatives and uses thereof for treatment of neurodegenerative diseases | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598338-B2 | Myricanol derivatives and uses thereof for treatment of neurodegenerative diseases | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150051294-A1 | Myricanol Derivatives and Uses Thereof for Treatment of Neurodegenerative Diseases | UNIVERSTIY OF SOUTH FLORIDA (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150051294-A1 | Myricanol Derivatives and Uses Thereof for Treatment of Neurodegenerative Diseases | UNIVERSTIY OF SOUTH FLORIDA (US) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051294-A1 | Myricanol Derivatives and Uses Thereof for Treatment of Neurodegenerative Diseases | MAPT, APP, PSEN2 | NFKB1 4111/4885NFKB2 4268/4885RELA 4321/4885 |
| US-10358405-B2 | Myricanol derivatives and uses thereof for treatment of neurodegenerative diseases | MAPT, APP, PSEN2 | NFKB1 4111/4885NFKB2 4268/4885RELA 4321/4885 |
| US-20180037529-A1 | Myricanol Derivatives and Uses Thereof for Treatment of Neurodegenerative Diseases | MAPT, APP, PSEN2 | NFKB1 4111/4885NFKB2 4268/4885RELA 4321/4885 |
| US-20190218165-A1 | Myricanol Derivatives and Uses Thereof for Treatment of Neurodegenerative Diseases | MAPT, APP, PSEN1 | NFKB1 3731/4885NFKB2 3984/4885RELA 4182/4885 |
| US-10287227-B2 | Myricanol derivatives and uses thereof for treatment of neurodegenerative diseases | MAPT, APP, PSEN2 | NFKB1 4111/4885NFKB2 4268/4885RELA 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.